Fibrinolytic Treatment of Acute Ischemic Stroke for Patients on New Oral Anticoagulant Drugs

The antifibrinolytic function of factor XIII is exclusively expressed through  2-antiplasmin cross-linking

(2011) S. R. Fraser et al.   BLOOD

Effects on fibrin network porosity of anticoagulants with different modes of action and reversal by activated coagulation factor concentrate*

(2011) Margareta Blombäck et al.   BRITISH JOURNAL OF HAEMATOLOGY

Fatal Intracerebral Hemorrhage Associated with Administration of Recombinant Tissue Plasminogen Activator in a Stroke Patient on Treatment with Dabigatran

(2011) Ignacio Casado Naranjo et al.   CEREBROVASCULAR DISEASES

Dabigatran Versus Warfarin in Patients With Atrial Fibrillation

(2011) Rangadham Nagarakanti et al.   CIRCULATION

Laboratory assessment of new anticoagulants

(2011) Meyer M. Samama et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Kinetics of Activated Thrombin-activatable Fibrinolysis Inhibitor (TAFIa)-catalyzed Cleavage of C-terminal Lysine Residues of Fibrin Degradation Products and Removal of Plasminogen-binding Sites

(2011) Jonathan H. Foley et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Apixaban in Patients with Atrial Fibrillation

(2011) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apixaban versus Warfarin in Patients with Atrial Fibrillation

(2011) Christopher B. Granger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

(2011) Manesh R. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Thrombolysis treatment for acute ischaemic stroke in a patient on treatment with dabigatran

(2011) María Consuelo Matute et al.   THROMBOSIS AND HAEMOSTASIS

Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: Two observational studies in patients undergoing total hip or total knee replacement

(2011) Geneviève Freyburger et al.   THROMBOSIS RESEARCH

Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48)

(2010) Christian T. Ruff et al.   AMERICAN HEART JOURNAL

The interplay between tissue plasminogen activator domains and fibrin structures in the regulation of fibrinolysis: kinetic and microscopic studies

(2010) C. Longstaff et al.   BLOOD

Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator in a Stroke Patient Treated with Dabigatran

(2010) Ann De Smedt et al.   CEREBROVASCULAR DISEASES

Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor

(2010) C. T. AMMOLLO et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Assays for Measuring Rivaroxaban: Their Suitability and Limitations

(2010) Edelgard Lindhoff-Last et al.   THERAPEUTIC DRUG MONITORING

An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma

(2010) Jean Amiral et al.   THROMBOSIS AND HAEMOSTASIS

Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor

(2010) Jean-Luc Martinoli et al.   THROMBOSIS AND HAEMOSTASIS

Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays

(2010) Fariba Baghaei et al.   THROMBOSIS AND HAEMOSTASIS

Drop of PT Quick percent value is associated with both symptomatic and asymptomatic intracranial hemorrhage in patients treated with rt-PA for acute ischemic stroke

(2010) A. Alonso et al.   THROMBOSIS RESEARCH

Intravenous Tissue Plasminogen Activator for Stroke: A Review of the ECASS III Results in Relation to Prior Clinical Trials

(2009) Carolyn A. Cronin   JOURNAL OF EMERGENCY MEDICINE

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Argatroban enhances fibrinolysis by differential inhibition of thrombin-mediated activation of thrombin activatable fibrinolysis inhibitor and factor XIII

(2008) Vance G Nielsen et al.   BLOOD COAGULATION & FIBRINOLYSIS

Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke

(2008) Werner Hacke et al.   NEW ENGLAND JOURNAL OF MEDICINE